Notch Therapeutics
Emily Titus is Vice President, Process Sciences at Notch Therapeutics. Previously, she was Vice President, Technology Advancement at CCRM, where she built cell reprogramming, genome engineering, and pluripotent stem cell differentiation programs and led the formation of Notch Therapeutics as part of CCRM’s company incubation program. Emily earned a PhD from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, where she used a combination of laboratory and bioinformatics approaches to define and interpret gene regulatory networks controlling embryonic stem cell fate decisions.
This person is not in any offices
Notch Therapeutics
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.